NDC 0006-4094-01 - RECOMBIVAX HB
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0006-4094
- Requested NDC
- 0006-4094-01
- Package NDCs from labels
- 0006-4094-01, 0006-4094-02
- Manufacturer
- Merck Sharp & Dohme LLC
- Effective date
- 2024-10-31
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| RECOMBIVAX HB - Merck Sharp & Dohme LLC | Merck Sharp & Dohme LLC | 2024-10-31 | VACCINE LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0006-4094-01 | RECOMBIVAX HB | 1 mL in 1 SYRINGE | INJECTION, SUSPENSION | 1 | 32 | |
| 0006-4094-02 | RECOMBIVAX HB | 10 in 1 CARTON | INJECTION, SUSPENSION | 10 | 32 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0006-4094-01 | ML - Milliliter | 0006-4094 | c25a9048-31c0-4d85-96d8-e7607da545a8 | 1 | 2014-08-01 |
| 0006-4094-02 | ML - Milliliter | 0006-4094 | 49491561-33fe-4edc-8516-315aed238ae3 | 1 | 2014-08-01 |
| 0006-4094-09 | ML - Milliliter | 0006-4094 | 81959c94-7e44-4807-9dec-426df875a254 | 1 | 2013-02-13 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| HEPATITIS B VIRUS SUBTYPE ADW HBSAG SURFACE PROTEIN ANTIGEN | ACTIVE INGREDIENT | XL4HLC6JH6 | RECOMBIVAX HB (HEPATITIS B VACCINE (RECOMBINANT)) INJECTION, SUSPENSION [MERCK SHARP & DOHME CORP.] | 19 | |
| HEPATITIS B VIRUS SUBTYPE ADW HBSAG SURFACE PROTEIN ANTIGEN | ACTIVE MOIETY | XL4HLC6JH6 | RECOMBIVAX HB (HEPATITIS B VACCINE (RECOMBINANT)) INJECTION, SUSPENSION [MERCK SHARP & DOHME CORP.] | 19 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| SEGLUROMET | ERTUGLIFLOZIN AND METFORMIN HYDROCHLORIDE | Merck Sharp & Dohme LLC | a6aeb99a-ce49-4125-90ce-642df3f1ebad | 2026-08-11 | Boxed warning, Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| JANUMET XR | SITAGLIPTIN AND METFORMIN HYDROCHLORIDE | Merck Sharp & Dohme LLC | 64beb3d2-3aeb-4cd5-ba11-dacf6c9a5b50 | 2026-08-11 | Boxed warning, Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| JANUMET | SITAGLIPTIN AND METFORMIN HYDROCHLORIDE | Merck Sharp & Dohme LLC | d19c7ed0-ad5c-426e-b2df-722508f97d67 | 2026-08-11 | Boxed warning, Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| KEYTRUDA QLEX | PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH | Merck Sharp & Dohme LLC | 097d166f-b73b-41d3-9b37-7653cd2a0c41 | 2026-07-31 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| LIPFENDRA | LIPFENDRA | Merck Sharp & Dohme LLC | 100ec543-fbd0-44fc-b740-db9cdff39145 | 2026-07-15 | Adverse reactions | Merck Sharp & Dohme LLC |
| KEYTRUDA | PEMBROLIZUMAB | Merck Sharp & Dohme LLC | 9333c79b-d487-4538-a9f0-71b91a02b287 | 2026-07-10 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| PIFELTRO | DORAVIRINE | Merck Sharp & Dohme LLC | 76ce1f00-28c0-4314-bd2c-d473fe3d0970 | 2026-07-08 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| DELSTRIGO | DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE | Merck Sharp & Dohme LLC | cd1e9f84-607a-46d3-b01e-2736018d67b6 | 2026-07-08 | Boxed warning, Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| STEGLATRO | ERTUGLIFLOZIN | Merck Sharp & Dohme LLC | e6f3e718-bb99-48f1-ab94-b9f0af05fed6 | 2026-06-03 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| STEGLUJAN | ERTUGLIFLOZIN AND SITAGLIPTIN | Merck Sharp & Dohme LLC | c2c553d8-5a9d-4366-bf53-8bdb5a876d19 | 2026-06-03 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| ZERBAXA | CEFTOLOZANE AND TAZOBACTAM | Merck Sharp & Dohme LLC | 70ac1d90-eff3-4f0b-9f46-5846c571b32f | 2026-05-12 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| Ohtuvayre | ENSIFENTRINE | MERCK SHARP & DOHME LLC | e6433c98-41a0-4f99-8f7f-d0e9db6e3f40 | 2026-04-23 | Warnings, Adverse reactions | MERCK SHARP & DOHME LLC |
| IDVYNSO | DORAVIRINE, ISLATRAVIR | Merck Sharp & Dohme LLC | 11aaeb53-9848-433c-be7f-db8a5bc0b26f | 2026-04-20 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| ZEPATIER | ELBASVIR AND GRAZOPREVIR | Merck Sharp & Dohme LLC | 164dc02a-9180-426a-b8b5-04ab39d2bbd4 | 2026-03-13 | Boxed warning, Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| BRIDION | SUGAMMADEX | Merck Sharp & Dohme LLC | 5171d883-fe8f-482c-97ab-40b00975b64a | 2026-03-13 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| SIVEXTRO | TEDIZOLID PHOSPHATE | Merck Sharp & Dohme LLC | 75672079-589f-451a-bdbf-eaebcfcc80a9 | 2026-02-27 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| EMEND | FOSAPREPITANT DIMEGLUMINE | Merck Sharp & Dohme LLC | 8d66803a-6811-4c29-9c57-e16acfa87f21 | 2026-02-20 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| TICE BCG | BACILLUS CALMETTE-GUERIN | Merck Sharp & Dohme LLC | c9b74876-e665-442b-87ad-b7333bc9a67a | 2026-02-20 | Boxed warning, Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| TEMODAR | TEMOZOLOMIDE | Merck Sharp & Dohme LLC | 046a9011-3911-4d3f-a15f-fbb56d5aad56 | 2026-02-20 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| NOXAFIL | POSACONAZOLE | Merck Sharp & Dohme LLC | b073b082-7b57-4423-8c06-4fd4263d6f84 | 2026-02-13 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.